losartan and Proteinuria studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

Excerpt	Relevance	Reference
"As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD."	9.51	The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022)
"We conducted a post hoc analysis of results from a prospective trial in which the proteinuria-reducing effects of losartan and enalapril were compared."	9.41	Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. ( Bryant, CE; Hogg, RJ; Rajai, A; Webb, NJA, 2021)
"The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria."	9.24	FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017)
" In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)."	9.19	Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014)
"A previous subgroup analysis of a 12-week, double-blind study demonstrated that losartan significantly lowered proteinuria versus placebo and amlodipine and was well tolerated in children (1-17 years old) with proteinuria secondary to Alport syndrome."	9.17	Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. ( Gleim, GW; Lam, C; Massaad, R; McCrary Sisk, C; Shahinfar, S; Webb, NJ; Wells, TG, 2013)
" Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria."	9.16	Losartan and enalapril are comparable in reducing proteinuria in children. ( Gleim, GW; Lam, C; Massaad, R; Santoro, EP; Shahinfar, S; Sisk, CM; Webb, NJ; Wells, TG, 2012)
"Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14."	9.15	Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011)
" There is currently little information available on the efficacy, safety, and individual tolerance of patients with post-diarrheal hemolytic uremic syndrome (D+ HUS) nephropathy to therapies involving diet, enalapril, or losartan."	9.15	Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. ( Caletti, MG; Exeni, R; Grignoli, M; Missoni, M; Piantanida, JJ; Rasse, SM; Repetto, HA; Vezzani, C, 2011)
"Losartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD."	9.15	Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease. ( Cho, S; Huh, W; Jang, HR; Kim, DJ; Kim, SR; Kim, YG; Lee, JE; Lee, YJ; Oh, HY, 2011)
"Twelve weeks of treatment with losartan significantly reduced proteinuria compared with amlodipine/placebo: losartan -35."	9.14	Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010)
"A prospective, open label, parallel group and randomized study was conducted to see the effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients."	9.14	Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. ( Hoque, R; Iqbal, M; Rahman, MS, 2009)
"Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure."	9.14	Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010)
"73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital."	9.13	Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008)
"The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood."	9.12	Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006)
"In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes."	9.12	Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006)
"In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy."	9.12	Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007)
" The aim of this study was to evaluate the effects of low-dose (25 mg) losartan on proteinuria and tubular injury extent."	9.11	Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. ( Lysiak-Szydłowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2005)
"We conclude that pravastatin administration is associated with improved proteinuria probably by inhibiting urine ET-1 levels in patients with losartan-based treatment."	9.11	Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. ( Chang, NC; Lee, TM; Lin, MS; Tsai, CH, 2005)
"Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria."	9.10	Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002)
" The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment."	9.10	Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003)
"To investigate the effect of the angiotensin II receptor antagonist losartan on proteinuria in secondary amyloidosis cases."	9.10	Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2002)
" The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria."	9.10	Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003)
"Efficacy of losartan in reducing proteinuria and in preserving renal function was prospectively assessed in 52 consecutive children under 18 years of age with chronic proteinuric renal disorders, an initial creatinine clearance > or =25 mL/min/1."	9.10	Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. ( Ellis, D; Grosso, MJ; Janosky, JE; Moritz, ML; Reitz, S; Vats, A, 2003)
" In this study, we intended to study the effect of losartan, as an ATII receptor antagonist, on proteinuria and renal functions in patients with normotensive secondary amyloidosis."	9.09	Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. ( Bilen, H; Cetinkaya, R; Odabas, AR; Selcuk, Y, 2001)
"To study the effects of the angiotensin II receptor antagonist losartan on the lipid profile of patients with nephrotic range proteinuria."	9.08	Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. ( de Jong, PE; de Zeeuw, D; Dullaart, RP; Gansevoort, RT, 1995)
"Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago."	8.83	Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006)
" Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations."	7.81	Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"Losartan and enalapril may be beneficial in pediatric kidney transplant recipients by decreasing blood pressure and proteinuria, with maintenance of stable graft function, but may be associated with serious adverse events including hyperkalemia and life-threatening acidosis."	7.80	Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. ( Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014)
" The AT(1) receptor for angiotensin II (Ang II) is involved in the renal expression of the nuclear factor-kappa B (NF-ΚB) during this nephrosis."	7.77	Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. ( Hernández-Fonseca, JP; Mosquera, J; Muñoz, M; Pedreañez, A; Rincón, J; Viera, N, 2011)
"The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments."	7.76	Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010)
" With the use of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study database as an example, the influence of baseline proteinuria on the primary composite endpoint, ESRD, and ESRD or death after adjusting for baseline proteinuria as a continuous covariate was examined."	7.73	Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Brenner, BM; de Zeeuw, D; Dickson, TZ; Gleim, GW; Keane, WF; Mogensen, CE; Ramjit, D; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005)
"An important explanatory theory for the mechanism of postexercise proteinuria is that angiotensin II could be inhibited by angiotensin converting enzyme inhibitors."	7.73	Angiotensin II inhibition attenuates postexercise proteinuria in rats. ( Gündüz, F; Kuru, O; Sentürk, UK, 2005)
" After the stabilization of proteinuria at the sixth week, the rats were treated for 6 weeks by losartan (n = 10, 30 mg/kg/day), HBO (n = 10, 2."	7.73	Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. ( Acikel, C; Aktug, H; Caglar, K; Eyileten, T; Ikizler, TA; Kaya, A; Korkmaz, A; Oguz, Y; Oter, S; Sonmez, A; Topal, T; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2006)
" This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan."	7.73	Acute renal failure during lisinopril and losartan therapy for proteinuria. ( Hanevold, CD, 2006)
" Secondary objectives were to evaluate changes in components of the renin-angiotensin axis and the effects of administration of losartan on pregnancy outcome."	7.72	Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat. ( Boner, G; Erman, A; Gafter, U; Natif, N; Sclarovsky-Benjaminov, F; Sulkes, J; Van Dijk, DJ, 2003)
" In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure."	7.70	Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998)
" daily for 3 weeks) and angiotensin II antagonist (losartan, 2 mg/kg bw in the same way) on experimental nephrotic syndrome induced in rats by the administration of adriamycin (5 mg/kg bw i."	7.70	[Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. ( Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 1999)
"Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR."	6.74	Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009)
"Proteinuria was significantly lower at 12 months in the losartan group than in the control group (p=0."	6.73	Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. ( Nitta, K; Shimizu, A; Takei, T; Tsuchiya, K; Uchida, K, 2008)
"Carvedilol was not found to be as effective as ACEIs and AT1ras in decreasing proteinuria and preserving renal function."	6.73	Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria. ( Akdag, I; Arabul, M; Dilek, K; Ersoy, A; Gullulu, M; Kahvecioglu, S; Yavuz, M; Yurtkuran, M, 2007)
"In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure."	6.73	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008)
" An open-label, dose-response study using subsequent 6-week treatment periods was performed in 10 nondiabetic patients with proteinuria of 5."	6.70	Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. ( de Jong, PE; de Zeeuw, D; Henning, RH; Laverman, GD; Navis, G, 2001)
"As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD."	5.51	The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022)
"Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-α,IL-6 and TNF-α."	5.46	Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. ( Gao, R; Li, X; Wen, Y; Wu, W, 2017)
"We conducted a post hoc analysis of results from a prospective trial in which the proteinuria-reducing effects of losartan and enalapril were compared."	5.41	Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. ( Bryant, CE; Hogg, RJ; Rajai, A; Webb, NJA, 2021)
"Proteinuria is the most common clinical manifestation of glomerular diseases."	5.40	Role of CD2-associated protein in podocyte apoptosis and proteinuria induced by angiotensin II. ( Huang, L; Wu, W; You, YS, 2014)
"Proteinuria was diagnosed in 2003 (DPE 3."	5.35	[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008)
"The proteinuria is frequently the initial insult to the kidney and it usually followed by a progressive decline in the glomerular filtration rate."	5.32	[The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria]. ( Canepa, C; De Reyes, V; Dieguez, SM; Liern, M; Vallejos, G, 2004)
"Losartan was administered for a period of 14."	5.31	Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. ( Calviño, J; Lens, XM; Romero, R; Sánchez-Guisande, D, 2000)
"Apparently, when hypertension is sustained, reappearance of target organ damage may not be entirely dependent on angiotensin."	5.31	Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. ( Blezer, EL; Joles, JA; Koomans, HA; Nicolay, K, 2001)
"Losartan treatment decreased the tissue expression of miR-21 and TGF-β and tissue fibrosis in kidney transplant patient, and it had a protective effect on allograft function and may delay chronic allograft dysfunction by reducing mediators of fibrosis."	5.27	Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. ( Nafar, M; Samavat, S; Shahraki, E, 2018)
"The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria."	5.24	FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017)
"MMF did not reduce proteinuria significantly in patients with IgAN who had persistent proteinuria after lisinopril/losartan plus Omacor."	5.20	Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. ( Appel, G; Bay, RC; Carter, B; Cattran, D; Cerda, J; Fervenza, FC; Fischer, D; Gipson, D; Hernandez, G; Hogg, RJ; Hurley, RM; Jennette, JC; Jung, B; Kumar, S; Sibley, R; Wyatt, RJ, 2015)
" In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)."	5.19	Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014)
"The results of this trial will provide solid data for use in evidence-based medicine with respect to the efficacy and safety of Shenyankangfu tablets for control of proteinuria in patients with primary glomerulonephritis compared to those of losartan potassium."	5.19	Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial. ( Cai, GY; Chen, XM; Deng, YY; Fang, JA; He, YN; Kou, J; Lin, HL; Nie, LF; Wu, J; Xie, YS; Yang, HT, 2014)
"To evaluate the clinical efficacy of syndrome differentiation-based treatment with traditional Chinese medicine (TCM) versus losartan therapy in addition to basic treatment for management of proteinuria in patients with chronic kidney disease."	5.17	[Syndrome differentiation-based treatment with traditional Chinese medicine for proteinuria in patients with chronic kidney disease: a randomized multicenter trial]. ( Bi, Y; He, L; Mi, X; Peng, W; Wang, D; Wang, Y; Wu, T; Xie, T; Yuan, M, 2013)
"A previous subgroup analysis of a 12-week, double-blind study demonstrated that losartan significantly lowered proteinuria versus placebo and amlodipine and was well tolerated in children (1-17 years old) with proteinuria secondary to Alport syndrome."	5.17	Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. ( Gleim, GW; Lam, C; Massaad, R; McCrary Sisk, C; Shahinfar, S; Webb, NJ; Wells, TG, 2013)
"Aliskiren confers an antiproteinuric effect in IgAN patients with significant residual proteinuria, despite receiving the recommended renoprotective treatment."	5.16	Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. ( Au, WS; Ho, YW; Lai, KN; Lin, M; Ma, MK; Tam, S; Tang, SC; Yap, DY, 2012)
" Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria."	5.16	Losartan and enalapril are comparable in reducing proteinuria in children. ( Gleim, GW; Lam, C; Massaad, R; Santoro, EP; Shahinfar, S; Sisk, CM; Webb, NJ; Wells, TG, 2012)
" Data from the Renoprotection of Optimal Antiproteinuric Doses (ROAD) trial were used to examine the contribution of the antiproteinuric effect of benazepril and losartan on renal outcome (the primary composite end point of doubling of serum creatinine and end-stage renal disease or death) in 339 Chinese nondiabetic CKD patients with overt proteinuria and renal insufficiency."	5.15	High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease. ( Fu, BL; Hou, FF; Liang, M; Xie, D; Zhang, X, 2011)
"Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14."	5.15	Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011)
" There is currently little information available on the efficacy, safety, and individual tolerance of patients with post-diarrheal hemolytic uremic syndrome (D+ HUS) nephropathy to therapies involving diet, enalapril, or losartan."	5.15	Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. ( Caletti, MG; Exeni, R; Grignoli, M; Missoni, M; Piantanida, JJ; Rasse, SM; Repetto, HA; Vezzani, C, 2011)
"Losartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD."	5.15	Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease. ( Cho, S; Huh, W; Jang, HR; Kim, DJ; Kim, SR; Kim, YG; Lee, JE; Lee, YJ; Oh, HY, 2011)
"0] g/24 h proteinuria) were treated during 6-week periods with placebo, ARB (100 mg/d losartan), and ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide) combined with consecutively regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na(+)/d)."	5.15	Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. ( Goldschmeding, R; Hemmelder, MH; Laverman, GD; Navis, G; Nguyen, TQ; Slagman, MC; Vogt, L; Waanders, F, 2011)
"Urinary KIM-1 level was increased in patients with nondiabetic CKD with proteinuria and decreased in parallel with proteinuria by using losartan, sodium restriction, their combination, losartan plus HCT, and the latter plus sodium restriction."	5.14	Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. ( Bonventre, JV; Damman, K; Hamming, I; Leuvenink, H; Navis, G; Vaidya, VS; van Goor, H; Vogt, L; Waanders, F, 2009)
" A total of 30 patients with type II diabetes, along with hypertension and overt nephropathy, were enrolled in this randomized, two-period, crossover trial of 12 weeks of treatment with losartan (50 mg daily) and telmisartan (40 mg daily)."	5.14	Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. ( Azuma, K; Dejima, T; Kanaoka, T; Maeda, A; Masuda, S; Ohsawa, M; Tamura, K; Umemura, S; Wakui, H; Yanagi, M, 2009)
"Twelve weeks of treatment with losartan significantly reduced proteinuria compared with amlodipine/placebo: losartan -35."	5.14	Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010)
"A prospective, open label, parallel group and randomized study was conducted to see the effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients."	5.14	Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. ( Hoque, R; Iqbal, M; Rahman, MS, 2009)
"Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure."	5.14	Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010)
" We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy."	5.13	Aliskiren combined with losartan in type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008)
"73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital."	5.13	Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008)
"The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood."	5.12	Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006)
"In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes."	5.12	Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006)
"In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy."	5.12	Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007)
"The study shows that combination therapy with very small doses of losartan and benazepril was more effective in reducing proteinuria than greater doses of either agent in monotherapy, and this greater antiproteinuric efficacy was independent of changes in BP."	5.11	Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. ( Korejwo, G; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zdrojewski, Z, 2004)
" The aim of this study was to evaluate the effects of low-dose (25 mg) losartan on proteinuria and tubular injury extent."	5.11	Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. ( Lysiak-Szydłowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2005)
"This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects."	5.11	Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005)
"We conclude that pravastatin administration is associated with improved proteinuria probably by inhibiting urine ET-1 levels in patients with losartan-based treatment."	5.11	Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. ( Chang, NC; Lee, TM; Lin, MS; Tsai, CH, 2005)
" Mean arterial pressure and proteinuria were reduced significantly during losartan treatment, but without concomitant changes in peripheral cortisol metabolism."	5.10	11beta-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade. ( Buter, H; Dullaart, RP; Kerstens, MN; Navis, GJ, 2002)
"To this purpose, lisinopril and losartan were studied in 9 nondiabetic renal patients with median proteinuria 4."	5.10	Dual renin-angiotensin system blockade at optimal doses for proteinuria. ( de Jong, PE; de Zeeuw, D; Henning, RH; Laverman, GD; Navis, G, 2002)
"Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria."	5.10	Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002)
" The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment."	5.10	Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003)
"To investigate the effect of the angiotensin II receptor antagonist losartan on proteinuria in secondary amyloidosis cases."	5.10	Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2002)
" The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria."	5.10	Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003)
"Efficacy of losartan in reducing proteinuria and in preserving renal function was prospectively assessed in 52 consecutive children under 18 years of age with chronic proteinuric renal disorders, an initial creatinine clearance > or =25 mL/min/1."	5.10	Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. ( Ellis, D; Grosso, MJ; Janosky, JE; Moritz, ML; Reitz, S; Vats, A, 2003)
"In this randomized double-blind crossover trial we compared the antiproteinuric effects of enalapril and losartan in six children with proteinuria and underlying renal injury."	5.10	Antiproteinuric effects of enalapril and losartan: a pilot study. ( Hurley, RM; Macpherson, CF; Matsell, DG; White, CT, 2003)
"Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases."	5.10	Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003)
"We tested this for the AIIA losartan using a prospective single-blind randomized design in patients with proteinuria (>1 g/24 h) due to non-diabetic chronic renal failure (stable creatinine clearance >20 ml/min) and mild to moderate hypertension (130/80 < blood pressure < 160/110 mmHg)."	5.10	The antiproteinuric effect of losartan is systemic blood pressure dependent. ( Crowe, AV; Howse, M; Kemp, GJ; Vinjamuri, S; Williams, PS, 2003)
"Add-on losartan therapy did not improve proteinuria or ABP over one month of add on therapy."	5.09	Add-on angiotensin receptor blockade with maximized ACE inhibition. ( Agarwal, R, 2001)
"To study the effects of the angiotensin II receptor antagonist losartan on the lipid profile of patients with nephrotic range proteinuria."	5.08	Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. ( de Jong, PE; de Zeeuw, D; Dullaart, RP; Gansevoort, RT, 1995)
"The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy."	5.08	Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998)
" The effects of losartan and enalapril were studied in eleven patients with non-diabetic proteinuria and hypertension."	5.07	Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? ( de Jong, PE; de Zeeuw, D; Gansevoort, RT, 1994)
"Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago."	4.83	Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006)
"Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria."	4.82	Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003)
" Losartan stabilized all of these parameters and hindered the progression of fibrosis, but it did not reverse the pre-existing fibrotic manifestations."	3.81	Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"Losartan and enalapril may be beneficial in pediatric kidney transplant recipients by decreasing blood pressure and proteinuria, with maintenance of stable graft function, but may be associated with serious adverse events including hyperkalemia and life-threatening acidosis."	3.80	Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. ( Baskın, E; Bayrakcı, US; Haberal, M; Moray, G; Sakallı, H, 2014)
" Patients were administered either losartan or placebo, each in addition to conventional antihypertensive therapy, with dosage adjustments as necessary to achieve a target blood pressure of less than 140/less than 90 mm Hg."	3.80	Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. ( Keane, WF; Lyle, PA, 2003)
" As proteinuria persisted, losartan was added at a median dose of 1."	3.79	Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. ( Balestracci, A; Caletti, MG; Missoni, M; Vezzani, C, 2013)
" This subanalysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study included 7629 patients, in whom the serum creatinine level was measured at least twice."	3.78	Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. ( Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2012)
" The AT(1) receptor for angiotensin II (Ang II) is involved in the renal expression of the nuclear factor-kappa B (NF-ΚB) during this nephrosis."	3.77	Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. ( Hernández-Fonseca, JP; Mosquera, J; Muñoz, M; Pedreañez, A; Rincón, J; Viera, N, 2011)
"The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments."	3.76	Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. ( Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z, 2010)
"Non-diabetic patients with proteinuria (>1 g/day) received 50 mg of losartan daily followed by 100 mg in two treatment periods, each lasting 12 weeks."	3.75	Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases. ( An, HR; Choi, HY; Ha, SK; Han, DS; Kim, BS; Lee, JS; Park, HC, 2009)
"These preliminary results suggest a possible influence of CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan."	3.75	CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. ( Blaisdell, J; Boyette, T; Candiani, C; Dornbrook-Lavender, K; Falk, RJ; Goldstein, JA; Hilliard, T; Hogan, SL; Hu, Y; Joy, MS, 2009)
"Mean proteinuria decreased from 484 +/- 290 mg/mmol creatinine to 223 +/- 197 after 1-3 months of losartan treatment and remained stable at 234 +/- 153, 224 +/- 177 and 195 +/- 133 after 3-6, 6-12 months and at the last follow-up check (median 1."	3.75	Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. ( John, U; Misselwitz, J; Pohl, M; Seeman, T, 2009)
"This article presents clinical data which suggest that the current dosage of losartan 50 to 100 mg/day may not be the optimum in many cases, especially if used as monotherapy in the treatment of proteinuria and we may have to increase to 200 mg/day."	3.73	ATRA therapy restores normal renal function and renal reserve and prevents renal failure. ( Chan, CM; Lau, YK; Wong, KS; Woo, KT, 2005)
" With the use of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study database as an example, the influence of baseline proteinuria on the primary composite endpoint, ESRD, and ESRD or death after adjusting for baseline proteinuria as a continuous covariate was examined."	3.73	Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Brenner, BM; de Zeeuw, D; Dickson, TZ; Gleim, GW; Keane, WF; Mogensen, CE; Ramjit, D; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005)
" Na and Cr excretions were decreased, while proteinuria and plasma ET-1 levels were normalized by losartan treatment, suggesting that renin-angiotensin system activation may have a role in leptin induced renal changes."	3.73	Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. ( Akgun, H; Dursun, N; Gunduz, Z; Koc, N; Okur, H; Ozturk, F, 2005)
"Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes."	3.73	[Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005)
"An important explanatory theory for the mechanism of postexercise proteinuria is that angiotensin II could be inhibited by angiotensin converting enzyme inhibitors."	3.73	Angiotensin II inhibition attenuates postexercise proteinuria in rats. ( Gündüz, F; Kuru, O; Sentürk, UK, 2005)
" After the stabilization of proteinuria at the sixth week, the rats were treated for 6 weeks by losartan (n = 10, 30 mg/kg/day), HBO (n = 10, 2."	3.73	Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. ( Acikel, C; Aktug, H; Caglar, K; Eyileten, T; Ikizler, TA; Kaya, A; Korkmaz, A; Oguz, Y; Oter, S; Sonmez, A; Topal, T; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2006)
" This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan."	3.73	Acute renal failure during lisinopril and losartan therapy for proteinuria. ( Hanevold, CD, 2006)
"The present study evaluates the participation of oxidative stress, tissue angiotensin II (Ang II) and endothelin (ET) in the effects of losartan on blood pressure (BP), ventricular hypertrophy and renal injury in spontaneously hypertensive rats (SHRs), and explores how these effects are modified when spontaneous hypertension is transformed in a low-renin model by the administration of deoxycorticosterone acetate (DOCA)."	3.72	Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats. ( Chamorro, V; Duarte, J; O'Valle, F; Osuna, A; Sainz, J; Vargas, F; Wangensteen, R, 2004)
" Secondary objectives were to evaluate changes in components of the renin-angiotensin axis and the effects of administration of losartan on pregnancy outcome."	3.72	Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat. ( Boner, G; Erman, A; Gafter, U; Natif, N; Sclarovsky-Benjaminov, F; Sulkes, J; Van Dijk, DJ, 2003)
"Arterial hypertension significantly decreased after the introduction of losartan (p = 0."	3.72	Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. ( Anaya, F; Campistol, JM; Del Castillo, D; Esforzado, N; Iñigo, P; Navarro, MD; Oppenheimer, F; Saracho, R, 2003)
"We report three cases of focal glomerular sclerosis (FGS) with proteinuria that improved with the administration of angiotensin type 1 receptor blocker (ARB, losartan or valsartan)."	3.72	[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis]. ( Chihara, Y; Fujimori, T; Iidaka, K; Inada, H; Ishimitsu, T; Matsuoka, H; Ogihara, T; Ono, H; Ono, Y; Rakugi, H; Ueda, Y, 2004)
" MASSIVE PROTEINURIA: An angiotensin II inhibitor, losartan, has been found to be effective against massive proteinuria (> 3."	3.71	[Complications in kidney transplantation]. ( Ouali, N, 2001)
" Enalapril and losartan reduced proteinuria but nifedipine did not."	3.71	Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. ( Campbell, DJ; Mackie, FE; Meyer, TW, 2002)
" In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure."	3.70	Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998)
" daily for 3 weeks) and angiotensin II antagonist (losartan, 2 mg/kg bw in the same way) on experimental nephrotic syndrome induced in rats by the administration of adriamycin (5 mg/kg bw i."	3.70	[Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. ( Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 1999)
"To study the effects of renin-angiotensin system blockade by a novel non-peptide angiotensin II receptor antagonist, losartan, on development of hypertension and acceleration of end-organ damage in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP)."	3.68	Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. ( Camargo, MJ; Campbell, WG; James, GD; Laragh, JH; Pecker, MS; Timmermans, PB; von Lutterotti, N, 1993)
"Proteinuric diabetic kidney disease frequently progresses to ESRD."	2.80	BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. ( Emanuele, NV; Fried, LF; Guarino, P; Leehey, DJ; Palevsky, PM; Reilly, RF; Whaley-Connell, A; Zhang, JH, 2015)
" No serious adverse events occurred in any of the 3 groups."	2.76	Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. ( Chen, P; Chen, X; Huang, S; Li, Y; Lie, C; Liu, S; Miao, L; Wang, L; Wu, X; Xie, Y; Zhang, A, 2011)
"Proteinuria is a common presentation of mesangioproliferative glomerulonephritis (MsPGN)."	2.76	Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up. ( Caglioti, C; Casoria, V; Comi, N; Conte, G; Fuiano, G; Fuiano, L; Iodice, C; Minutolo, R; Presta, P, 2011)
"Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR."	2.74	Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009)
"Proteinuria was significantly lower at 12 months in the losartan group than in the control group (p=0."	2.73	Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. ( Nitta, K; Shimizu, A; Takei, T; Tsuchiya, K; Uchida, K, 2008)
"Carvedilol was not found to be as effective as ACEIs and AT1ras in decreasing proteinuria and preserving renal function."	2.73	Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria. ( Akdag, I; Arabul, M; Dilek, K; Ersoy, A; Gullulu, M; Kahvecioglu, S; Yavuz, M; Yurtkuran, M, 2007)
" Patients received open-label treatment with a conventional dosage of benazepril (10 mg/d), individual uptitration of benazepril (median 20 mg/d; range 10 to 40), a conventional dosage of losartan (50 mg/d), or individual uptitration of losartan (median 100 mg/d; range 50 to 200)."	2.73	Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. ( Chen, PY; Guo, ZJ; Hou, FF; Jiang, JP; Liang, M; Xie, D; Zhang, WR; Zhang, X, 2007)
"In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure."	2.73	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008)
"Levels of proteinuria were reduced with losartan compared with placebo, with an overall losartan treatment effect of 37."	2.72	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. ( Chan, JC; Cooper, ME; Keane, WF; Kurokawa, K; Shahinfar, S; Zhang, Z, 2006)
"The etiology of CKD was type 2 diabetes mellitus in 12 and glomerulonephritis in 4 patients."	2.71	Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. ( Agarwal, R, 2003)
"The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0."	2.71	An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003)
"Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2."	2.71	Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for ( Hayashi, M; Ideura, T; Iino, Y; Kawaguchi, Y; Kawamura, T; Kitajima, T; Koyama, A; Kuwahara, M; Shiigai, T; Sugisaki, T; Suzuki, H; Tomino, Y; Uchida, S; Umemura, S; Yamada, K; Yamazaki, T, 2003)
"In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, approximately 17% of patients were Asians."	2.71	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. ( Brenner, BM; Chan, JC; Chua, CT; Cooper, ME; Dickson, TZ; Hille, D; Kurokawa, K; Lam, KS; Morad, Z; Shahinfar, S; So, WY; Wat, NM; Wong, KS; Zhang, Z, 2004)
"Losartan was used in 45 consecutive hypertensive children with chronic renal parenchymal disorders and mean glomerular filtration rate (GFR) 99."	2.71	Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. ( Ellis, D; Janosky, JE; Moritz, ML; Vats, A, 2004)
"Diabetic nephropathy is the leading cause of end-stage renal disease."	2.70	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001)
" An open-label, dose-response study using subsequent 6-week treatment periods was performed in 10 nondiabetic patients with proteinuria of 5."	2.70	Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. ( de Jong, PE; de Zeeuw, D; Henning, RH; Laverman, GD; Navis, G, 2001)
"Losartan was withdrawn in only 6 patients because ofa clinical or laboratory adverse experience."	2.69	Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. ( Mitchell, H; Raij, L; Ramjit, D; Shahinfar, S; Shaw, W; Shultz, P; Toh, J; Toto, R, 1998)
" Clinical evaluations and laboratory tests were performed (1) before CEI treatment (basal) and after (2) CEI alone (CEI, 12 weeks); (3) the combination of CEI and LOS, the latter at a dosage of 50 mg/d (CEI + LOS, 4 weeks); (4) LOS alone (LOS; 50 mg/d; 12 weeks); (5) the combination of LOS and CEI (LOS + CEI, 4 weeks, at the same dosage as CEI + LOS); and (6) a doubled dose of either CEI alone or LOS alone for 4 weeks."	2.69	Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. ( Andreucci, M; Balletta, MM; De Nicola, L; Minutolo, R; Pisani, A; Russo, D; Savino, FA, 1999)
"Treatment with losartan (50 mg) was introduced."	2.69	Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. ( Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999)
"001)."	2.69	ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. ( Chiang, GS; Lau, YK; Wong, KS; Woo, KT, 2000)
" There were no dose-response renal effects of losartan."	2.45	Inhibition of the renin-angiotensin system: is more better? ( Anderson, S; Komers, R, 2009)
"Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 microg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality."	2.45	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. ( Bichu, P; Khan, A; Nistala, R; Sowers, JR; Whaley-Connell, A, 2009)
"Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease."	2.43	Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006)
"The major goal of treating high blood pressure in this population is to prevent or reduce the likelihood of target-organ damage."	2.42	Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? ( Lakkis, J; Lu, WX; Weir, MR, 2003)
"For patients with type 2 diabetes mellitus (T2DM) and hypertension, an AII receptor blocker (AIIRB) is recommended as the first drug that should be used."	2.42	Advances in the treatment of diabetic renal disease: focus on losartan. ( Rayner, B, 2004)
"Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy."	2.41	The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002)
"Hypertension is highly prevalent after renal transplantation and has been associated with lower graft survival."	2.41	Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. ( Anaya, F; Del Castillo, D; Holgado, R, 2001)
"Podocyte loss and proteinuria are both key features of human diabetic nephropathy (DN)."	1.56	Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. ( Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA, 2020)
"Losartan 50 mg/d was used to control proteinuria under the close watch of serum creatinine."	1.51	[The 467th case: proteinuria, periungual fibromas, and facial steatadenomas]. ( Chen, G; Dong, QR; Li, MX; Li, XM, 2019)
"Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-α,IL-6 and TNF-α."	1.46	Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. ( Gao, R; Li, X; Wen, Y; Wu, W, 2017)
" Both single treatments significantly improved systemic and kidney antioxidant defense, bioavailability of renal nitric oxide, reduced kMMP-1 protein expression and renal injury, thus retarded CKD progression."	1.43	Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. ( Grujic-Milanovic, J; Ivanov, M; Jovovic, D; Karanovic, D; Markovic-Lipkovski, J; Mihailovic-Stanojevic, N; Miloradovic, Z; Vajic, UJ; Zivotic, M, 2016)
"Proteinuria is the most common clinical manifestation of glomerular diseases."	1.40	Role of CD2-associated protein in podocyte apoptosis and proteinuria induced by angiotensin II. ( Huang, L; Wu, W; You, YS, 2014)
"Enalapril was found to be more reno-protective compared to losartan."	1.40	COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL. ( Mugendi, GA; Mwangi, M; Ndwiga, S; Nyamu, DG; Nyamweya, NN; Okalebo, FA, 2014)
"Losartan treatment also decreased ANG II and TGF-β."	1.39	Renin angiotensin system blockade ameliorates lead nephropathy. ( Chiou, TT; Hsu, CY; Huang, PC; Lee, CT; Lee, YT; Ng, HY; Tain, YL, 2013)
"While proteinuria was reduced in all four of these patients by 45, 96, 53, and 64%, respectively, three patients experienced side effects requiring changes in the aliskiren dose."	1.37	Are we ready to use aliskiren in children? ( Filler, G; Kelland, EE; McAuley, LM, 2011)
"Captopril and losartan were equally effective as mitigators, with DMFs of 1."	1.37	Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation. ( Cohen, EP; Fish, BL; Moulder, JE, 2011)
"Overt proteinuria is a strong risk factor for thromboembolism, owing to changes in the levels of various coagulation proteins and urinary antithrombin loss."	1.37	The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. ( Kluin-Nelemans, HC; Laverman, GD; Mahmoodi, BK; Mulder, AB; Mulder, R; Navis, G; Slagman, MC; Spronk, HM; Ten Cate, H; Vogt, L; Waanders, F, 2011)
"Proteinuria was decreased in groups MR and AR compared with group P (on day 14 after PAN administration, respectively; group P vs AR, P < 0."	1.36	Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. ( Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K, 2010)
"Proteinuria was diagnosed in 2003 (DPE 3."	1.35	[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008)
"Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group."	1.35	Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. ( Aizawa, Y; Arozal, W; Kodama, M; Ma, M; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2009)
"Recent immunosuppressive treatments for lupus nephritis have improved renal survival rate, however, there still exists lupus nephritis refractory to these treatments."	1.33	Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. ( Kanda, H; Kubo, K; Mimura, T; Sato, K; Tateishi, S; Yamamoto, K; Yonezumi, A, 2005)
"Treatment with losartan not only reduced the incidence of ESRD, but also can result in substantial cost savings in the European Union."	1.31	Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002)
"Losartan was administered for a period of 14."	1.31	Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. ( Calviño, J; Lens, XM; Romero, R; Sánchez-Guisande, D, 2000)
"Reduction of proteinuria is a prerequisite for successful long-term renoprotection."	1.31	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. ( Andersen, S; Bos, H; De Jong, PE; De Zeeuw, D; Navis, G; Parving, HH; Rossing, P, 2000)
"Apparently, when hypertension is sustained, reappearance of target organ damage may not be entirely dependent on angiotensin."	1.31	Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. ( Blezer, EL; Joles, JA; Koomans, HA; Nicolay, K, 2001)
"Patients with chronic renal failure are restricted to mild physical activity and tend to a lack of exercise."	1.31	Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. ( Kamimoto, M; Kanazawa, M; Kawamura, T; Kohzuki, M; Kurosawa, H; Minami, N; Mori, N; Nagasaka, M; Saito, T; Wu, XM; Xu, HL; Yoshida, K, 2001)
"Proteinuria was measured at four weeks after 5/6 renal ablation, and rats were then divided into a group which received the Ang II receptor blocker MK954 and a group which received no treatment."	1.29	Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. ( Deen, WM; Lafayette, RA; Mayer, G; Meyer, TW; Myers, BD; Oliver, J, 1993)
" Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age."	1.29	Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993)
"Proteinuria was markedly reduced in both strains by L."	1.29	Losartan protects the rat kidney from ischemic injury. ( Cervenka, L; Heller, J; Hellerová, S; Kramer, HJ, 1996)

Research

Studies (240)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	25 (10.42)	18.2507
2000's	145 (60.42)	29.6817
2010's	63 (26.25)	24.3611
2020's	7 (2.92)	2.80

Authors	Studies
Yoo, TH	2
Hong, SJ	1
Kim, S	1
Shin, S	1
Kim, DK	1
Lee, JP	1
Han, SY	1
Lee, S	2
Won, JC	1
Kang, YS	1
Park, J	1
Han, BG	1
Na, KR	1
Hur, KY	1
Kim, YJ	2
Park, S	2
Cooper, TE	1
Teng, C	1
Tunnicliffe, DJ	1
Cashmore, BA	1
Strippoli, GF	1
Huang, WJ	1
Meng, X	1
Yang, F	1
Bao, Q	1
Zhang, MZ	1
Yang, YN	1
Ni, Q	1
Lian, FM	1
Tong, XL	1
Binz-Lotter, J	1
Jüngst, C	1
Rinschen, MM	1
Koehler, S	1
Zentis, P	1
Schauss, A	1
Schermer, B	1
Benzing, T	1
Hackl, MJ	1
Shiozaki, Y	1
Fujikura, T	1
Isobe, S	1
Takatsuka, I	1
Sato, T	1
Goto, D	1
Ishigaki, S	1
Ohashi, N	1
Yasuda, H	1
Hudkins, KL	1
Wietecha, TA	1
Steegh, F	1
Alpers, CE	1
Bryant, CE	1
Rajai, A	1
Webb, NJA	1
Hogg, RJ	2
Awazu, M	1
Yamada, M	1
Asada, N	1
Hashiguchi, A	1
Kosaki, K	1
Matsumura, K	1
Gao, R	1
Wu, W	2
Wen, Y	1
Li, X	1
Kim, JY	1
Son, JW	1
Ryu, DR	1
Chin, HJ	1
Shima, Y	1
Nakanishi, K	1
Sako, M	1
Saito-Oba, M	1
Hamasaki, Y	1
Hataya, H	1
Honda, M	1
Kamei, K	1
Ishikura, K	1
Ito, S	2
Kaito, H	1
Tanaka, R	1
Nozu, K	1
Nakamura, H	1
Ohashi, Y	1
Iijima, K	1
Yoshikawa, N	1
Nafar, M	1
Samavat, S	1
Shahraki, E	1
Chen, G	1
Dong, QR	1
Li, MX	1
Li, XM	1
Gutiérrez, E	1
Alvarez, M	1
Ardiles, L	1
Reyes-Pardo, H	1
Bautista, R	2
Vargas-Robles, H	1
Rios, A	1
Sánchez, D	1
Escalante, B	2
Wang, D	1
Wu, T	1
Xie, T	1
Peng, W	3
Wang, Y	4
Yuan, M	2
Mi, X	1
Bi, Y	1
He, L	1
Ng, HY	1
Tain, YL	1
Lee, YT	1
Hsu, CY	1
Chiou, TT	1
Huang, PC	1
Lee, CT	1
Sakallı, H	1
Baskın, E	1
Bayrakcı, US	1
Moray, G	1
Haberal, M	1
Zhong, Y	1
Zhang, X	3
Cai, X	1
Wang, K	1
Chen, Y	1
Deng, Y	1
Arnoni, CP	1
Maquigussa, E	1
Passos, CS	1
Pereira, LG	1
Boim, MA	1
Woo, KT	5
Choong, HL	1
Wong, KS	6
Tan, HK	1
Foo, M	1
Fook-Chong, S	1
Lee, EJ	1
Anantharaman, V	1
Lee, GS	1
Chan, CM	4
Fujisaki, K	1
Tsuruya, K	1
Nakano, T	1
Taniguchi, M	1
Higashi, H	1
Katafuchi, R	1
Kanai, H	1
Nakayama, M	1
Hirakata, H	1
Kitazono, T	1
Huang, L	1
You, YS	1
Hung, KW	1
Blaine, J	1
Faubel, S	1
Arruda-Junior, DF	1
Virgulino, SG	1
Girardi, AC	1
Kou, J	1
Wu, J	1
Yang, HT	1
He, YN	1
Fang, JA	1
Deng, YY	1
Xie, YS	1
Nie, LF	3
Lin, HL	1
Cai, GY	1
Chen, XM	1
Wu, H	1
Liang, Y	1
Zheng, Y	1
Bai, Q	1
Zhuang, Z	1
A, L	1
Zheng, D	1
Wu, F	1
Zhang, PQ	2
Wang, XQ	2
Fu, XJ	2
Li, J	3
Bi, YP	2
Mi, XH	2
Ding, XQ	1
He, LQ	3
Mohapatra, A	1
Matthai, SM	1
Vijayakumar, K	1
Basu, G	1
Bay, RC	1
Jennette, JC	1
Sibley, R	1
Kumar, S	1
Fervenza, FC	1
Appel, G	1
Cattran, D	1
Fischer, D	1
Hurley, RM	2
Cerda, J	1
Carter, B	1
Jung, B	1
Hernandez, G	1
Gipson, D	1
Wyatt, RJ	1
Leehey, DJ	1
Zhang, JH	2
Emanuele, NV	1
Whaley-Connell, A	2
Palevsky, PM	2
Reilly, RF	1
Guarino, P	1
Fried, LF	2
Dai, Q	1
Mugendi, GA	1
Nyamu, DG	1
Okalebo, FA	1
Nyamweya, NN	1
Ndwiga, S	1
Mwangi, M	1
Karanovic, D	1
Grujic-Milanovic, J	1
Miloradovic, Z	1
Ivanov, M	1
Jovovic, D	1
Vajic, UJ	1
Zivotic, M	1
Markovic-Lipkovski, J	1
Mihailovic-Stanojevic, N	1
Parving, HH	5
Persson, F	1
Lewis, JB	1
Lewis, EJ	1
Hollenberg, NK	1
Ingelfinger, JR	3
Lin, SL	2
Chen, YM	2
Chiang, WC	2
Wu, KD	2
Tsai, TJ	2
Panesar, M	1
Damodar, A	1
Lindner, T	1
Anderson, S	2
Komers, R	2
de Zeeuw, D	10
Gansevoort, RT	3
Dullaart, RP	4
de Jong, PE	6
Waanders, F	7
Vaidya, VS	1
van Goor, H	1
Leuvenink, H	1
Damman, K	2
Hamming, I	1
Bonventre, JV	1
Vogt, L	8
Navis, G	10
Renke, M	4
Rutkowski, P	4
Tylicki, L	5
Zietkiewicz, M	1
Larczyński, W	1
Rutkowski, B	5
Shimizu, A	1
Takei, T	1
Uchida, K	1
Tsuchiya, K	1
Nitta, K	1
Perico, N	3
Cattaneo, D	1
Remuzzi, G	8
Duckworth, W	1
O'Connor, T	1
Brophy, M	1
Emanuele, N	1
Huang, GD	1
McCullough, PA	1
Seliger, S	1
Warren, SR	1
Peduzzi, P	1
Guo, LL	1
Pan, Y	2
Jin, HM	2
Akman, S	1
Kalay, S	1
Akkaya, B	1
Koyun, M	1
Akbaş, H	1
Baysal, YE	1
Guven, AG	1
Park, HC	3
Choi, HY	2
Kim, BS	3
An, HR	1
Lee, JS	1
Ha, SK	3
Han, DS	3
Kim, KS	1
Fan, WH	1
Kim, YD	1
Zhu, W	1
Ngau, YY	1
Tong, P	1
Santos, M	1
Lin, WH	1
Buranakitjaroen, P	1
Massaad, R	3
Smith, RD	2
Krikken, JA	1
Dallinga-Thie, GM	1
Dikkeschei, LD	1
Navis, GJ	2
Bichu, P	1
Nistala, R	1
Khan, A	1
Sowers, JR	1
Inserra, F	1
Basso, N	1
Ferder, M	1
Userpater, M	1
Stella, I	1
Paglia, N	1
Inserra, P	1
Tenembaum, D	1
Ferder, L	1
Zoja, C	1
Corna, D	1
Rottoli, D	1
Gaspari, F	1
Haskell, L	1
Arozal, W	1
Watanabe, K	1
Veeraveedu, PT	1
Ma, M	1
Thandavarayan, RA	1
Suzuki, K	2
Tachikawa, H	1
Kodama, M	1
Aizawa, Y	1
Joy, MS	1
Dornbrook-Lavender, K	1
Blaisdell, J	1
Hilliard, T	1
Boyette, T	1
Hu, Y	1
Hogan, SL	1
Candiani, C	1
Falk, RJ	1
Goldstein, JA	1
Abe, M	1
Okada, K	1
Maruyama, T	1
Matsumoto, K	1
Masuda, S	1
Tamura, K	1
Wakui, H	1
Kanaoka, T	1
Ohsawa, M	1
Maeda, A	1
Dejima, T	1
Yanagi, M	1
Azuma, K	1
Umemura, S	3
Seeman, T	1
Pohl, M	1
Misselwitz, J	1
John, U	1
Naito, T	1
Ma, LJ	2
Yang, H	2
Zuo, Y	1
Tang, Y	1
Han, JY	1
Kon, V	1
Fogo, AB	2
Webb, NJ	4
Lam, C	4
Loeys, T	1
Shahinfar, S	14
Strehlau, J	2
Wells, TG	4
Santoro, E	1
Manas, D	1
Gleim, GW	5
Hoque, R	1
Rahman, MS	1
Iqbal, M	1
Kosmadakis, G	1
Filiopoulos, V	1
Georgoulias, C	1
Tentolouris, N	1
Michail, S	1
Slagman, MC	4
Sinkeler, SJ	1
Hemmelder, MH	2
Kluin-Nelemans, HC	2
Laverman, GD	7
Wang, H	1
Deng, JL	1
Yue, J	1
Hou, YB	1
Thornton, SN	1
Fukuda, A	1
Fujimoto, S	1
Iwatsubo, S	1
Kawachi, H	1
Kitamura, K	1
Rakusan, D	2
Kujal, P	2
Kramer, HJ	3
Husková, Z	2
Vanourková, Z	2
Vernerová, Z	3
Mrázová, I	1
Thumová, M	1
Cervenka, L	4
Vanecková, I	2
Chábová, VČ	1
Walkowska, A	1
Kompanowska-Jezierska, E	1
Sadowski, J	1
Opočenský, M	1
Skaroupková, P	1
Schejbalová, S	1
Malý, J	1
Netuka, I	1
Kopkan, L	1
Xie, D	2
Hou, FF	2
Fu, BL	1
Liang, M	2
Guo, DZ	1
Dong, BA	1
Wang, YH	1
Lai, KN	3
Chan, LY	1
Guo, H	1
Tang, SC	2
Leung, JC	1
Kelland, EE	1
McAuley, LM	1
Filler, G	2
Moulder, JE	1
Cohen, EP	1
Fish, BL	1
Le Bailly De Tilleghem, C	1
Xie, Y	1
Huang, S	1
Wang, L	2
Miao, L	1
Zhang, A	1
Li, Y	1
Wu, X	1
Liu, S	1
Lie, C	1
Chen, P	1
Chen, X	1
Caletti, MG	2
Missoni, M	2
Vezzani, C	2
Grignoli, M	1
Piantanida, JJ	1
Repetto, HA	1
Exeni, R	1
Rasse, SM	1
Park, HW	1
Kim, Y	1
Kim, KH	1
Rozen, S	1
Najafian, B	1
Mauer, M	1
Lin, M	1
Tam, S	1
Au, WS	1
Ma, MK	1
Yap, DY	1
Ho, YW	1
Muñoz, M	1
Rincón, J	1
Pedreañez, A	1
Viera, N	1
Hernández-Fonseca, JP	1
Mosquera, J	1
Lee, YJ	1
Cho, S	1
Kim, SR	1
Jang, HR	1
Lee, JE	1
Huh, W	1
Kim, DJ	1
Oh, HY	1
Kim, YG	1
Nguyen, TQ	1
Goldschmeding, R	1
Hemmelder, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage[NCT03009864]	Early Phase 1	632 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397]	Phase 4	40 participants (Anticipated)	Interventional	2022-07-01	Recruiting
[NCT02620306]	Phase 3	351 participants (Actual)	Interventional	2016-02-11	Completed
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial[NCT02063100]	Phase 4	720 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria[NCT00097955]	Phase 2	496 participants	Interventional	2004-10-31	Completed
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)[NCT00555217]	Phase 3	1,448 participants (Actual)	Interventional	2008-07-31	Terminated (stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.)
An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy[NCT00354991]	Phase 3	437 participants (Actual)	Interventional	2006-06-01	Completed
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension[NCT00568178]	Phase 3	306 participants (Actual)	Interventional	2007-06-01	Completed
Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study[NCT00922311]	Phase 4	25 participants (Actual)	Interventional	2009-07-31	Completed
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886]	Phase 4	28 participants (Actual)	Interventional	2016-09-30	Completed
Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis[NCT01115426]	Phase 4	20 participants (Actual)	Interventional	1997-01-31	Completed
A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985]	Phase 4	97 participants (Actual)	Interventional	2000-02-29	Completed
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347]	Phase 3	1,513 participants (Actual)	Interventional	1996-05-31	Completed
[NCT03019848]	Phase 2	100 participants (Anticipated)	Interventional	2016-05-31	Recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)[NCT03317925]		29 participants (Actual)	Observational	2014-07-16	Completed
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial[NCT01552954]	Phase 4	269 participants (Actual)	Interventional	2012-02-29	Completed
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt N[NCT00168857]	Phase 4	860 participants (Actual)	Interventional	2003-07-09	Completed
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562]	Phase 4	20 participants	Interventional	1996-01-31	Completed
Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-25	Recruiting
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695]	Phase 4	40 participants (Anticipated)	Interventional	2021-07-21	Recruiting
Determinants of Diabetic Nephropathy in American Indians[NCT01878045]		141 participants (Actual)	Observational	2013-11-07	Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Time to the first event of reduction in estimated GFR of 30ml/min/1.73m*m in individuals w/a baseline estimated GFR >= 60 ml/min/1.73m*m, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73m*m; ESRD or death. (NCT00555217)
Timeframe: From enrollemnt to time of first primary event, up to 4.5 years

A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.

Intervention	participants (Number)
Combination of ARB and ACEI	132
Monotherapy ARB	152

Time to the first event of reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD. (NCT00555217)
Timeframe: From enrollment to time of first event, up to 4.5 years

Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12

Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12

Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12

Intervention	participants (Number)
Combination of ARB and ACEI	77
Monotherapy ARB	101

Intervention	mm Hg (Least Squares Mean)
Losartan-Hypertensive Participants	-3.8
Amlodipine-Hypertensive Participants	0.8

Intervention	mm Hg (Least Squares Mean)
Losartan-Hypertensive Participants	-5.5
Amlodipine-Hypertensive Participants	-0.1

"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately twelve weeks of treatment.~Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period." (NCT00568178)
Timeframe: Baseline and Week 12

Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36

Intervention	Percent Change in Pr/Cr (Geometric Mean)
Losartan	-35.80
Amlodipine/Placebo	1.37

"The outcome measure of glomerular filtration rate was based on mL/min/1.73m^2, as determined by the Schwartz formula:~GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL)~GFR values were compared to the baseline GFR measure.~[Note: For male participants, ages 13 to 17 years, 0.70 was used as~the multiplier in place of 0.55]~Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36

Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36

Intervention	Change in GFR mL/min1.73m^2 (Least Squares Mean)
Losartan Open Label Extension	3.3
Enalapril Open Label Extension	7.0

"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately three years of treatment.~*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Intervention	Percent Change in Pr/Cr (Geometric Mean)
Losartan Open Label Extension	-30.01
Enalapril Open Label Extension	-40.45

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

∆Albuminuria by 24-hour Urine Protein Excretion

Intervention	kg (Mean)
Insulin Glargine, Metformin, Exenatide	-4.8
Insulin Glargine, Metformin, Prandial Insulin	0.7

"Change in albuminuria as a 24-hour urine protein excretion by intensive education of low salt diet during taking olmesartan~*In outcome measure data table, the 24-hour urine collection at 16th week was omitted in 3 out of 245 patients (1 for intensive education group and 2 for conventional education group). Values of each study week were mean of all participants on specific study week, but ∆albuminuria (week 8 - week 16) value was mean of ∆ values of 8 weeks-16 weeks in each individuals. Therefore, values of 3 patients were excluded in mean of ∆albuminuria (week 8 - week 16). That's why simple subtraction (week 8 - week 16) of values are not matched with the data." (NCT01552954)
Timeframe: changes from week 8 at week 16 (week 8 - week 16)

∆Hemoglobin (0 Week - 16 Weeks)

Intervention	mg/day (Mean)
	24hr-urine albumin (8th week)	24hr-urine albumin (16th week);n=124, 118	Mean of ∆albuminuria (week 8-week 16); n=124, 118
Conventional Education of Low-salt Diet Group	483.5	487.3	-0.4
Intensive Education of Low-salt Diet Group	569.9	417.4	154.0

The change of hemoglobin after prescription of Olmesartan (NCT01552954)
Timeframe: 0 week, 16 weeks

Na Excretion Change in 24 Hour-urine Collection Between Weeks 8 and 16

Intervention	g/dL (Mean)
	Hemoglobin (week 0)	Hemoglobin (week 8)	Hemoglobin (week 16)	Hemoglobin changes from week 0 at week 16
Conventional Education of Low-salt Diet Group	13.8	13.5	13.3	0.46
Intensive Education of Low-salt Diet Group	14.0	13.7	13.4	0.62

Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet at week 16 (NCT01552954)
Timeframe: week 8 and week 16

Systolic and Diastolic Blood Pressure Change Between Weeks 8 and 16

Intervention	mEq/day (Mean)
	week 8	week 16; n=124, 118	∆Na excretion (week 8 - week 16);n=124, 118
Conventional Education of Low-salt Diet Group	155.5	147.1	9.0
Intensive Education of Low-salt Diet Group	157.4	122.1	35.4

Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16 in the Intensive Education Group compared to the Conventional Education Group (NCT01552954)
Timeframe: week 8 and week 16

Intervention	mm Hg (Mean)
	Systolic BP at week 8	Systolic BP at week 16	sBP changes from week 8 at week 16	Diastolic BP at week 8	Diastolic BP at week 16	dBP changes from week 8 at week 16
Conventional Education of Low-salt Diet Group	121.8	121.2	0.6	73.4	74.8	-0.7
Intensive Education of Low-salt Diet Group	122.1	120.4	1.7	73.6	73.1	0.5

Article	Year
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. The Cochrane database of systematic reviews, 2023, 07-19, Volume: 7 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus	2023
Inhibition of the renin-angiotensin system: is more better? Kidney international, 2009, Volume: 75, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Dose-Response Relationship	2009
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabe	2009
Clinical trials of the past decade in the management of chronic kidney disease. Reviews on recent clinical trials, 2009, Volume: 4, Issue:3 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyper	2009
Prostaglandin E1 for preventing the progression of diabetic kidney disease. The Cochrane database of systematic reviews, 2010, May-12, Issue:5 Topics: Albuminuria; Alprostadil; Diabetic Nephropathies; Disease Progression; Drugs, Chinese Herbal; Fosino	2010
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clinical therapeutics, 2002, Volume: 24, Issue:7 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2002
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3 Suppl 1 Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney	2003
Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Current hypertension reports, 2003, Volume: 5, Issue:3 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2003
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial	2003
Advances in the treatment of diabetic renal disease: focus on losartan. Current medical research and opinion, 2004, Volume: 20, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv	2004
[Organ protection by angiotensin II receptor blockers]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;	2004
[Kidney and hypertension--evidence based medicine]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Aug-10, Volume: 93, Issue:8 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit	2004
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds	2006
Time to abandon microalbuminuria? Kidney international, 2006, Volume: 70, Issue:7 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers;	2006
[Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1999, Volume: 113, Issue:6 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chronic Disease; Clinical Trials	1999
Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16 Suppl 1 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic;	2001

Article	Year
Injured Podocytes Are Sensitized to Angiotensin II-Induced Calcium Signaling. Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Signaling; Cells, Cultured; Disease Model	2020
Case report: increased single-nephron estimated glomerular filtration rate in an adult patient with low birth weight. BMC nephrology, 2020, 03-04, Volume: 21, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Cell Count; Female; Glomerular Filtration Rate; Glomerulosc	2020
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. American journal of physiology. Renal physiology, 2020, 05-01, Volume: 318, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Ne	2020
A girl with a mutation of the ciliary gene CC2D2A presenting with FSGS and nephronophthisis. CEN case reports, 2022, Volume: 11, Issue:1 Topics: Child; Child, Preschool; Cytoskeletal Proteins; Female; Fibrosis; Glomerulosclerosis, Focal Segmenta	2022
Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. International urology and nephrology, 2017, Volume: 49, Issue:7 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antimalarials; Blood Pressure; Case-Control Studies;	2017
[The 467th case: proteinuria, periungual fibromas, and facial steatadenomas]. Zhonghua nei ke za zhi, 2019, Jan-01, Volume: 58, Issue:1 Topics: Angiomyolipoma; Apolipoprotein L1; Creatinine; Female; Glomerulonephritis, IGA; Humans; Kidney Failu	2019
IgA nephropathy: is a new approach beyond proteinuria necessary? Pediatric nephrology (Berlin, Germany), 2019, Volume: 34, Issue:5 Topics: Child; Glomerulonephritis, IGA; Humans; Lisinopril; Losartan; Proteinuria	2019
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease]. Revista medica de Chile, 2019, Volume: 147, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D	2019
Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage. BMC nephrology, 2019, 08-02, Volume: 20, Issue:1 Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Co	2019
Renin angiotensin system blockade ameliorates lead nephropathy. Biochemical and biophysical research communications, 2013, Aug-23, Volume: 438, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2013
Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2014, Volume: 12, Issue:4 Topics: Acidosis; Adolescent; Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E	2014
Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats. PloS one, 2014, Volume: 9, Issue:1 Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation,	2014
Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:3 Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cell Movement; Cell Transdifferentiation; Chole	2015
Role of CD2-associated protein in podocyte apoptosis and proteinuria induced by angiotensin II. Renal failure, 2014, Volume: 36, Issue:8 Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apopt	2014
Dual therapy difficulties in angiotensin blockade for proteinuria: a teachable moment. JAMA internal medicine, 2014, Volume: 174, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Drug	2014
Reduced tubular proteinuria in hypertensive rats treated with losartan is associated with higher renal cortical megalin expression. Hormone molecular biology and clinical investigation, 2014, Volume: 18, Issue:2 Topics: Animals; Antihypertensive Agents; Blood Pressure; Glomerular Filtration Barrier; Hydralazine; Kidney	2014
Up-regulation of intrarenal renin-agiotensin system contributes to renal damage in high-salt induced hypertension rats. Kidney & blood pressure research, 2014, Volume: 39, Issue:6 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Diet; Hypertensio	2014
Quiz page: an unusual cause of nephrotic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:1 Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension	2015
COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL. East African medical journal, 2014, Volume: 91, Issue:4 Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Diabetic Nephropathies; Enalapril; Female; Humans;	2014
Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. PloS one, 2016, Volume: 11, Issue:8 Topics: Animals; Antihypertensive Agents; Antioxidants; Cyclic N-Oxides; Drug Therapy, Combination; Female;	2016
Aliskiren and dual therapy in type 2 diabetes mellitus. The New England journal of medicine, 2008, Jun-05, Volume: 358, Issue:23 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2;	2008
Aliskiren combined with losartan in diabetes and nephropathy. The New England journal of medicine, 2008, Sep-04, Volume: 359, Issue:10 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates;	2008
Aliskiren combined with losartan in diabetes and nephropathy. The New England journal of medicine, 2008, Sep-04, Volume: 359, Issue:10 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyper	2008
Aliskiren combined with losartan in diabetes and nephropathy. The New England journal of medicine, 2008, Sep-04, Volume: 359, Issue:10 Topics: Amides; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Therapy,	2008
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. Przeglad lekarski, 2008, Volume: 65, Issue:6 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type	2008
Telmisartan is more effective than losartan in reducing proteinuria. Kidney international, 2009, Volume: 75, Issue:1 Topics: Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Losartan; Prote	2009
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr	2009
Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome. Pediatric nephrology (Berlin, Germany), 2009, Volume: 24, Issue:6 Topics: Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Drug Therapy, Combination; Enalapril;	2009
Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2009, Volume: 63, Issue:9 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Humans; Losartan; Male; Midd	2009
Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:5 Topics: Actins; Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I	2009
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney international, 2009, Volume: 76, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidiur	2009
Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Urea Nitrogen; Blotting, Western; Cardiomyop	2009
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. European journal of clinical pharmacology, 2009, Volume: 65, Issue:9 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aryl Hydrocarbon Hydr	2009
Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. Kidney & blood pressure research, 2009, Volume: 32, Issue:6 Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood	2009
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An	2010
RAAS blockade in combination with diuretic therapy increases urine excretion, which in turn increases drinking and thus reduces erythropoietin and proteinuria. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:7 Topics: Chronic Disease; Diuretics; Drinking Behavior; Drug Therapy, Combination; Erythropoietin; Hemodiluti	2010
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone	2010
Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. American journal of physiology. Renal physiology, 2010, Volume: 299, Issue:4 Topics: Amides; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Mode	2010
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:12 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme	2010
Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy. Pediatric nephrology (Berlin, Germany), 2011, Volume: 26, Issue:2 Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Drug Therapy	2011
Are we ready to use aliskiren in children? Pediatric nephrology (Berlin, Germany), 2011, Volume: 26, Issue:3 Topics: Adolescent; Age Factors; Amides; Angiotensin II Type 1 Receptor Blockers; Child, Preschool; Chronic	2011
Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation. Radiation research, 2011, Volume: 175, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Azotemia	2011
Angiotensin II receptor blocker pretreatment of rats undergoing sudden renal ablation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Glomerular Filtration Rate; Hypertension; Kidney D	2012
Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2011, Volume: 12, Issue:4 Topics: Angiotensin II; Animals; Cholesterol; Disease Models, Animal; Doxorubicin; Endothelin-1; Fluorescent	2011
The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:12 Topics: Adult; Double-Blind Method; Female; Humans; Losartan; Male; Middle Aged; Placebos; Proteinuria; Prot	2011
Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1. Cellular signalling, 2012, Volume: 24, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Blottin	2012
Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR. Pediatric nephrology (Berlin, Germany), 2012, Volume: 27, Issue:5 Topics: Abnormalities, Multiple; Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting	2012
Therapeutic resistance to ACEI and ARB combination in macroalbuminuric diabetic nephropathy. Clinical nephrology, 2012, Volume: 78, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies;	2012
Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertension research : official journal of the Japanese Society of Hypertension, 2012, Volume: 35, Issue:8 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascul	2012
Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatric nephrology (Berlin, Germany), 2013, Volume: 28, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Child, Pre	2013
Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2002, Volume: 283, Issue:5 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure;	2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney international. Supplement, 2002, Issue:82 Topics: Angiotensin II Type 1 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Diabe	2002
[Is one antihypertensive agent as good as another?]. MMW Fortschritte der Medizin, 2002, Nov-07, Volume: 144, Issue:45 Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Drug Therapy, Combination; Humans; Hypertension; Hy	2002
Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:2 Topics: Angiotensin II; Animals; Blood Pressure; Creatinine; Enzyme Inhibitors; Heart Rate; Hyperthyroidism;	2003
Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2003, Volume: 54, Issue:5-6 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Disease	2003
Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats. Clinical science (London, England : 1979), 2004, Volume: 106, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cardiomeg	2004
Insulin and losartan reduce proteinuria and renal hypertrophy in the pregnant diabetic rat. The Journal of laboratory and clinical medicine, 2003, Volume: 142, Issue:3 Topics: Angiotensin II; Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Drug Therapy, Com	2003
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment. Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:10 Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba	2003
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron. Clinical practice, 2003, Volume: 95, Issue:3 Topics: Anemia; Antihypertensive Agents; Cough; Creatinine; Female; Follow-Up Studies; Humans; Hyperkalemia;	2003
[Microalbuminuria is an early marker for increased morbidity and mortality]. Fortschritte der Medizin. Originalien, 2003, Feb-27, Volume: 121 Suppl 1 Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom	2003
Anti-proteinuric effect of losartan: statistical vs clinical significance. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:3 Topics: Amlodipine; Antihypertensive Agents; Data Interpretation, Statistical; Humans; Losartan; Proteinuria	2004
Tight blood pressure control decreases apoptosis during renal damage. Kidney international, 2004, Volume: 65, Issue:3 Topics: Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Division; Drug Therapy, Combinatio	2004
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. Nephron. Physiology, 2004, Volume: 97, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr	2004
Angiotensin II-dependent induction of AT(2) receptor expression after renal ablation. American journal of physiology. Renal physiology, 2005, Volume: 288, Issue:1 Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Pressure; Diuresis; Gene Exp	2005
[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis]. Nihon Jinzo Gakkai shi, 2004, Volume: 46, Issue:5 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diet, Protein-Restricted; D	2004
Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2004, Volume: 5, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes	2004
[The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2004, Volume: 24, Issue:6 Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Drug Therapy, Combination; Enalapril; Fe	2004
ATRA therapy restores normal renal function and renal reserve and prevents renal failure. Annals of the Academy of Medicine, Singapore, 2005, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Creatinine; Disease Progres	2005
Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus, 2005, Volume: 14, Issue:4 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres	2005
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:6 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropath	2005
Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. American journal of physiology. Renal physiology, 2005, Volume: 289, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Doxorubi	2005
Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:1 Topics: Adult; Analysis of Variance; Apolipoproteins; Biological Transport; Case-Control Studies; Cholestero	2006
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. Journal of hypertension, 2005, Volume: 23, Issue:10 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta, Thoracic; Blood Pressure; Blott	2005
Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:11 Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephri	2005
Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. Regulatory peptides, 2005, Dec-15, Volume: 132, Issue:1-3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Creatinine; Kidney; Kidney Disease	2005
[Pharmacogenetics of angiotensin system in non diabetic nephropathy]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25, Issue:4 Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel	2005
Angiotensin II inhibition attenuates postexercise proteinuria in rats. International journal of sports medicine, 2005, Volume: 26, Issue:9 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2005
Blood pressure and proteinuria after cessation of a brief renin-angiotensin system blockade in young and adult Lyon hypertensive rats. Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr	2005
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus, 2005, Volume: 14, Issue:12 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C	2005
RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney international, 2006, Volume: 69, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen;	2006
Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. Nephron. Experimental nephrology, 2006, Volume: 104, Issue:1 Topics: Animals; Doxorubicin; Drug Synergism; Hyperbaric Oxygenation; Kidney; Losartan; Male; Nephrotic Synd	2006
Acute renal failure during lisinopril and losartan therapy for proteinuria. Pharmacotherapy, 2006, Volume: 26, Issue:9 Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito	2006
Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:5 Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angio	2007
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment. Nephrology (Carlton, Vic.), 2008, Volume: 13, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chemokine CCL2; Cytokines; Female; Follow-Up St	2008
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:8 Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors	2008
Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney international, 1993, Volume: 43, Issue:2 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Dextr	1993
Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. Journal of cardiovascular pharmacology, 1993, Volume: 22, Issue:2 Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood	1993
Mechanism of ochratoxin A-induced reduction of glomerular filtration rate in rats. The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:1 Topics: Angiotensin II; Animals; Biphenyl Compounds; Glomerular Filtration Rate; Glycosuria; Hemodynamics; I	1993
Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:2 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu	1993
Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. Nephron, 1993, Volume: 65, Issue:3 Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen;	1993
Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. Journal of hypertension, 1993, Volume: 11, Issue:1 Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Proteins; Body Weight; Brain; Chlorides; Creatini	1993
Losartan protects the rat kidney from ischemic injury. Kidney international. Supplement, 1996, Volume: 55 Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Hypertension; Imid	1996
Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat. Kidney & blood pressure research, 1996, Volume: 19, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu	1996
Renal effects of an angiotensin II antagonist in stroke-prone spontaneously hypertensive rat. Nephron, 1997, Volume: 76, Issue:4 Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood	1997
Antiproteinuric effect of losartan in patients with chronic renal diseases. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:10 Topics: Chronic Disease; Humans; Kidney Diseases; Losartan; Proteinuria	1997
Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. Journal of the American Society of Nephrology : JASN, 1998, Volume: 9, Issue:2 Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bl	1998
Control of severe proteinuria with losartan after renal transplantation. American journal of nephrology, 1998, Volume: 18, Issue:3 Topics: Adolescent; Antihypertensive Agents; Humans; Kidney Transplantation; Losartan; Male; Postoperative C	1998
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. European journal of pharmacology, 1998, Dec-04, Volume: 362, Issue:2-3 Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B	1998
[Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis]. Terapevticheskii arkhiv, 1999, Volume: 71, Issue:6 Topics: Adolescent; Adult; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito	1999
[Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. Casopis lekaru ceskych, 1999, Oct-20, Volume: 138, Issue:18 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dinoprost; Doxorubicin; Eicosanoi	1999
Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:1 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Hemo	2000
Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats : possible role in renoprotection. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:3 Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Transformed; Disease Mo	2000
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney international. Supplement, 2000, Volume: 75 Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropa	2000
Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:4 Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals	2000
Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy. Nephron, 2000, Volume: 86, Issue:4 Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C	2000
Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. American journal of hypertension, 2001, Volume: 14, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Brain Edema; Drug Admini	2001
Anti-proteinuric effect of angiotension II receptor antagonist losartan in cases with glomerular lesions. Clinical nephrology, 2001, Volume: 55, Issue:3 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Glomerulonephritis; Humans; Kidne	2001
Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron, 2001, Volume: 88, Issue:3 Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diure	2001
IgA nephropathy and inhibitors of the renin angiotensin system: is reduction in proteinuria adequate proof of efficacy? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 38, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug The	2001
Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. Journal of the American Society of Nephrology : JASN, 2001, Volume: 12, Issue:9 Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Chronic Disease; Creatinine; Cyclosporine	2001
Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiological research, 2001, Volume: 50, Issue:4 Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bo	2001
[Complications in kidney transplantation]. Presse medicale (Paris, France : 1983), 2001, Sep-01, Volume: 30, Issue:24 Pt 2 Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Graft Rejection; Humans; H	2001
Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. Journal of hypertension, 2001, Volume: 19, Issue:10 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv	2001
Combined use of enalapril and losartan to reduce proteinuria: a question of safety. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 39, Issue:1 Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Child	2002
Preventing nephropathy in patients with type 2 diabetes. Managed care interface, 2002, Volume: 15, Issue:1 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty	2002
Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Kidney international, 2002, Volume: 61, Issue:2 Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykin	2002
Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatric nephrology (Berlin, Germany), 2002, Volume: 17, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Glomerulonephritis, IGA; Humans; Losartan;	2002
Contemporary medical options for treating patients with heart failure. Circulation, 2002, May-14, Volume: 105, Issue:19 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I	2002
Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. The Journal of clinical investigation, 1992, Volume: 90, Issue:3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;	1992

losartan and Proteinuria